Zeria Of Japan To Buy Tilotts Of Switzerland For $128 Million
This article was originally published in PharmAsia News
Japan's Zeria Pharma said it plans to buy Tilotts Pharma of Switzerland for just over $128 million. Zeria reportedly made the purchase to expand its drug pipeline and widen its marketing ability abroad. Tilotts is attractive to Zeria because of its Asacol (mesalamine) drug for treating hypersensitive bowel syndrome. The product is considered a good fit with Zeria's gastrointestinal line of drugs. Zeria has been developing and marketing Asacol in Japan for the past five years. The purchase of Tilotts gives the Japanese company rights to sell the drug in 53 countries. (Click here for more - a subscription may be required
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.